Table 1. Characteristics of the Trials Included in this Study.

First author	Year	Country	No. of patients	% males	Loss to follow-up (%)	Neurogenic disorders	Study design	T/C	Active treatment mean follow-up, wks	Level of evidence
Chancellor	2013	USA, UK	416	41.1	0	MS: n = 227,SCI: n = 189	Randomized, double-blind, placebo-controlled	200 U: n = 135,300 U: n = 132,Placebo: n = 149	6 w, 12 w	A
Cruz	2011	Europe, North America, South Africa	275	43.6	1.4	MS: n = 154,SCI: n = 121	Randomized,double-blind, placebo-controlled	200 U: n = 92,300 U: n = 91,Placebo: n = 92	2, 6, 12 and 52 w	A
Herschorn	2011	Canada	58	58.6	10	MS: n = 38,SCI: n = 19	Randomized, double-blind, placebo-controlled	300 U: n = 28,Placebo: n = 29	1, 3, 4, 6, 24 and 36 w	A
Ginsberg	2012	Europe, USA	416	41.1	2.2	MS: n = 227,SCI: n = 189	Randomized, double-blind, placebo-controlled	200 U: n = 135,300 U: n = 132,Placebo: n = 149	6 w, 12 w	A
Rovner	2013	USA	691	42.1	2	MS: n = 381,SCI: n = 310	Randomized, double-blind, placebo-controlled	200 U: n = 241,300 U: n = 227,Placebo: n = 223	2, 6, 12 and 52 w	A
Schurch	2005	Belgium, France	59	36	0	MS: n = 53,SCI: n = 6	Randomized, double-blind, placebo-controlled	200 U: n = 19,300 U: n = 19,Placebo: n = 21	2, 6, 12, 18 and 24 w	A

MS: multiple sclerosis; SCI: spinal cord injury; T/C: treatment/control.